EGFR and non-small cell lung carcinoma: Although EGFR tyrosine kinase inhibitors (TKIs) offer an effective treatment for patients with advanced NSCLC, therapeutic strategies to overcome acquired resistance to EGFR‐TKIs in NSCLC patients remains to be determined.